Overview

Dose-finding Study of KHK7791 in Hyperphosphatemia Patients

Status:
Completed
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the effect and safety of KHK7791 to treat Hyperphosphatemia in ptatients on HD.
Phase:
Phase 2
Details
Lead Sponsor:
Kyowa Hakko Kirin Co., Ltd
Kyowa Kirin Co., Ltd.